Saxena AR, Gorman DN, Esquejo RM et al (2021) Danuglipron (PF-06882961) in type 2 diabetes: a randomized placebo-controlled multiple ascending-dose phase 1 trial
doi: 10.1016/j.coph.2017.11.011 2
#WeightLossClinic #GLP1 #MedicalWeightLoss #PatientRetention #ClinicGrowth To view or add a comment, sign in VERY excited to learn more about this
10.1016/S1470-2045(16)00107-8 Lancet Oncol
By integrating and analyzing multi-omics data together, AI enables the discovery of novel biomarkers and new druggable targets, performs drug repurposing, and saves both cost and time with respect to conventional methods (306)
By analyzing pathways altered in the same direction in comorbid diseases, we propose hypotheses explaining differences in disease co-occurrence between sexes